IL22RA2 and carcinoma: In contrast to IL‐22RA1, IL‐22BP mRNA expression only increased during the initiation and hyperplasia stages (4–8 weeks) and decreased significantly from the early carcinoma stage to the late carcinoma stage (8–14 weeks) of tumor development (Fig. 4C).